OTCMKTS:GNMSF - Genmab A/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $227.20 -0.50 (-0.22 %) (As of 01/27/2020 03:08 PM ET) Add Compare Today's Range$227.20Now: $227.20▼$227.2050-Day Range$211.19MA: $222.04▼$239.2852-Week Range$143.80Now: $227.20▼$243.00Volume14 shsAverage Volume1,063 shsMarket Capitalization$14.02 billionP/E Ratio61.91Dividend YieldN/ABeta0.18 ProfileAnalyst RatingsAdvanced ChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. Read More… Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:GNMSF Previous Symbol CUSIPN/A CIKN/A Webhttp://www.genmab.com/ Phone45-7020-2728Debt Debt-to-Equity Ratio0.01 Current Ratio18.72 Quick Ratio18.72Price-To-Earnings Trailing P/E Ratio61.91 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$479.45 million Price / Sales29.23 Cash Flow$3.81 per share Price / Cash Flow59.67 Book Value$20.72 per share Price / Book10.97Profitability EPS (Most Recent Fiscal Year)N/A Net Income$233.19 million Net Margins42.03% Return on Equity16.46% Return on Assets15.40%Miscellaneous Employees377 Outstanding Shares61,690,000Market Cap$14.02 billion Next Earnings Date2/19/2020 (Estimated) OptionableNot Optionable Receive GNMSF News and Ratings via Email Sign-up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. OTC:GNMSF Rates by TradingView Genmab A/S (OTCMKTS:GNMSF) Frequently Asked Questions What is Genmab A/S's stock symbol? Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF." How were Genmab A/S's earnings last quarter? Genmab A/S (OTCMKTS:GNMSF) posted its quarterly earnings data on Wednesday, November, 6th. The company reported $1.23 earnings per share (EPS) for the quarter. The company had revenue of $154.91 million for the quarter. Genmab A/S had a net margin of 42.03% and a return on equity of 16.46%. View Genmab A/S's Earnings History. When is Genmab A/S's next earnings date? Genmab A/S is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Genmab A/S. Has Genmab A/S been receiving favorable news coverage? Press coverage about GNMSF stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Genmab A/S earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Genmab A/S. Who are some of Genmab A/S's key competitors? Some companies that are related to Genmab A/S include Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), UCB (UCBJF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA) and Beigene (BGNE). What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include Triumph Group (TGI), AerCap (AER), Novo Nordisk A/S (NVO), BAVARIAN NORDIC/S (BVNRY), GENMAB A/S/S (GMXAY), Genmab A/S (GMAB), Micron Technology (MU), ZEALAND PHARMA/S (ZEAL), Regeneron Pharmaceuticals (REGN) and Nektar Therapeutics (NKTR). Who are Genmab A/S's key executives? Genmab A/S's management team includes the folowing people: Dr. Jan G. J. van de Winkel, Co-Founder, CEO & Pres (Age 58)Mr. David A. Eatwell, Exec. VP & CFO (Age 58)Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (Age 61)Ms. Jane Juel, Sr. Director of Operations & Resource ManagementMr. Peter Ros, Sr. Director of Fin. & Accounting How do I buy shares of Genmab A/S? Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Genmab A/S's stock price today? One share of GNMSF stock can currently be purchased for approximately $227.20. How big of a company is Genmab A/S? Genmab A/S has a market capitalization of $14.02 billion and generates $479.45 million in revenue each year. Genmab A/S employs 377 workers across the globe.View Additional Information About Genmab A/S. What is Genmab A/S's official website? The official website for Genmab A/S is http://www.genmab.com/. How can I contact Genmab A/S? Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The company can be reached via phone at 45-7020-2728 or via email at [email protected] MarketBeat Community Rating for Genmab A/S (OTCMKTS GNMSF)Community Ranking: 1.9 out of 5 ()Outperform Votes: 152 (Vote Outperform)Underperform Votes: 240 (Vote Underperform)Total Votes: 392MarketBeat's community ratings are surveys of what our community members think about Genmab A/S and other stocks. Vote "Outperform" if you believe GNMSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMSF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: Pattern Day Trader - What is the PDT Rule?
